WO2000047559A3 - 5-ht1f agonists - Google Patents

5-ht1f agonists Download PDF

Info

Publication number
WO2000047559A3
WO2000047559A3 PCT/US2000/002502 US0002502W WO0047559A3 WO 2000047559 A3 WO2000047559 A3 WO 2000047559A3 US 0002502 W US0002502 W US 0002502W WO 0047559 A3 WO0047559 A3 WO 0047559A3
Authority
WO
WIPO (PCT)
Prior art keywords
ht1f agonists
ht1f
agonists
mammal
activating
Prior art date
Application number
PCT/US2000/002502
Other languages
French (fr)
Other versions
WO2000047559A2 (en
Inventor
Joseph Herman Krushinski Jr
Vincent Mancuso
Freddy Andre Napora
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Joseph Herman Krushinski Jr
Vincent Mancuso
Freddy Andre Napora
John Mehnert Schaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Joseph Herman Krushinski Jr, Vincent Mancuso, Freddy Andre Napora, John Mehnert Schaus filed Critical Lilly Co Eli
Priority to CA002360164A priority Critical patent/CA2360164A1/en
Priority to JP2000598480A priority patent/JP2002536434A/en
Priority to DE60036924T priority patent/DE60036924T2/en
Priority to BR0008112-4A priority patent/BR0008112A/en
Priority to EP00915719A priority patent/EP1153013B1/en
Priority to KR1020017010048A priority patent/KR20010102003A/en
Priority to AU36945/00A priority patent/AU770098B2/en
Priority to US09/890,741 priority patent/US6777428B1/en
Publication of WO2000047559A2 publication Critical patent/WO2000047559A2/en
Publication of WO2000047559A3 publication Critical patent/WO2000047559A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a compound of formula (I) and a process for making; or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
PCT/US2000/002502 1999-02-10 2000-02-09 5-ht1f agonists WO2000047559A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002360164A CA2360164A1 (en) 1999-02-10 2000-02-09 5-ht1f agonists
JP2000598480A JP2002536434A (en) 1999-02-10 2000-02-09 5-HT1F agonist
DE60036924T DE60036924T2 (en) 1999-02-10 2000-02-09 5-HT1F AGONISTS
BR0008112-4A BR0008112A (en) 1999-02-10 2000-02-09 5-ht 1f agonists
EP00915719A EP1153013B1 (en) 1999-02-10 2000-02-09 5-ht1f agonists
KR1020017010048A KR20010102003A (en) 1999-02-10 2000-02-09 5-HT1F Agonists
AU36945/00A AU770098B2 (en) 1999-02-10 2000-02-09 5-HT1F agonists
US09/890,741 US6777428B1 (en) 1999-02-10 2000-02-09 5-HT1f agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11959699P 1999-02-10 1999-02-10
US60/119,596 1999-02-10

Publications (2)

Publication Number Publication Date
WO2000047559A2 WO2000047559A2 (en) 2000-08-17
WO2000047559A3 true WO2000047559A3 (en) 2000-11-30

Family

ID=22385241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002502 WO2000047559A2 (en) 1999-02-10 2000-02-09 5-ht1f agonists

Country Status (11)

Country Link
EP (1) EP1153013B1 (en)
JP (1) JP2002536434A (en)
KR (1) KR20010102003A (en)
CN (1) CN1149195C (en)
AT (1) ATE377000T1 (en)
AU (1) AU770098B2 (en)
BR (1) BR0008112A (en)
CA (1) CA2360164A1 (en)
DE (1) DE60036924T2 (en)
ES (1) ES2295017T3 (en)
WO (1) WO2000047559A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273451C (en) * 2000-12-22 2006-09-06 先灵公司 Piperidine MCH antagonists and their use in treatment of obesity
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US7608629B2 (en) 2003-04-18 2009-10-27 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
CA2549007A1 (en) 2003-12-17 2005-07-07 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
WO2007115403A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
TW200914020A (en) * 2007-08-28 2009-04-01 Lilly Co Eli Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
WO2016027757A1 (en) * 2014-08-18 2016-02-25 国立大学法人大阪大学 Novel 2-aminbenzoyl derivative
TWI829107B (en) 2019-07-09 2024-01-11 美商美國禮來大藥廠 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
CN110981854B (en) * 2019-09-10 2023-03-28 南京三元阳普医药科技有限公司 Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound
CN114728929A (en) * 2019-11-22 2022-07-08 广东东阳光药业有限公司 Pyridine methylene piperidine derivatives and use thereof
CN111004214B (en) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 Pyridylpiperidine derivatives and use thereof
CN110845402B (en) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 Pyridine methylene piperazine derivatives and uses thereof
CN111187251B (en) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 Pyridinoylpiperidine derivatives and their use
CN111187252B (en) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 Pyridinoyl azaspiroheptane derivatives and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
EP0832650A2 (en) * 1996-09-18 1998-04-01 Eli Lilly And Company Use of serotonin 5-HT1F agonists for the prevention of migraine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
EP0832650A2 (en) * 1996-09-18 1998-04-01 Eli Lilly And Company Use of serotonin 5-HT1F agonists for the prevention of migraine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADHAM N ET AL: "CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F): A FIFTH 5-HT1RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE CYCLASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 90, no. 2, 15 January 1993 (1993-01-15), pages 408 - 412, XP000572279, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
DE60036924T2 (en) 2008-08-14
CA2360164A1 (en) 2000-08-17
JP2002536434A (en) 2002-10-29
EP1153013B1 (en) 2007-10-31
BR0008112A (en) 2001-11-13
CN1149195C (en) 2004-05-12
ATE377000T1 (en) 2007-11-15
DE60036924D1 (en) 2007-12-13
KR20010102003A (en) 2001-11-15
AU3694500A (en) 2000-08-29
WO2000047559A2 (en) 2000-08-17
EP1153013A2 (en) 2001-11-14
ES2295017T3 (en) 2008-04-16
AU770098B2 (en) 2004-02-12
CN1340045A (en) 2002-03-13

Similar Documents

Publication Publication Date Title
AU4831899A (en) 5-HT1F agonists
WO2000047559A3 (en) 5-ht1f agonists
WO2000006173A8 (en) 5-ht1f agonists
EE04060B1 (en) Heterocyclic compounds for inhibiting gastric acid secretion, process for their preparation and pharmaceutical compositions
HUP0300592A3 (en) Process for the preparation of 2-halobenzoic acid derivatives
WO2000000490A3 (en) 5-ht1f agonists
CA2341031A1 (en) Novel salt form of pantoprazole
DE60210552D1 (en) Process for the preparation of a solid pharmaceutical preparation containing a sparingly soluble active substance
AU6518998A (en) Morphinane derivatives and medicinal use thereof
AU2002319207A1 (en) Sialic acid derivatives for use as siglec inhibitors
WO2002018321A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
HUP0301080A3 (en) Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them
WO2000050426A3 (en) Furo[3, 2-b]pyridines as 5-ht1f agonists
WO2003020963A3 (en) Proteins in type 2 diabetes
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
HUP0103788A3 (en) Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
HUP9900344A3 (en) Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof
AU2001286163A1 (en) An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
WO2002018323A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
AU7958000A (en) Process for the preparation of oxyiminoalkanoic acid derivatives
TNSN00240A1 (en) Heterocyclic derivatives
HUP0000982A2 (en) Process for the preparation of 1,1-dioxo-penicillanic acid derivatives
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
HUP0201549A3 (en) Quinolinecarboxylic acid derivative or salts thereof and pharmaceutical compositions containing them
WO2003013530A3 (en) Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00803576.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000915719

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2360164

Country of ref document: CA

Ref document number: 2360164

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/797/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020017010048

Country of ref document: KR

Ref document number: PA/a/2001/008077

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 598480

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 36945/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000915719

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017010048

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09890741

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 36945/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017010048

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000915719

Country of ref document: EP